|
177Lu-PSMA-617 Clinical Trials
6 actively recruiting trials across 3 locations
▲ +2 trials since June 2026
Also known as: (177Lu)-PSMA-617, C49H71N9O16, Lutetium Lu 177 vipivotide tetraxetan, Lutetium-177 (177Lu)-PSMA-617, Lutetium-177-PSMA-617 +1 more
Pipeline
Phase 1: 4Phase 2: 2
Top Sponsors
- University of California, San Francisco2
- Weill Medical College of Cornell University1
- Memorial Sloan Kettering Cancer Center1
- Jean-Mathieu Beauregard1
- European Organisation for Research and Treatment of Cancer - EORTC1
Indications
- Cancer6
- Prostate Cancer3
- Liver Disease1
- Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype1
- Diffuse Hemispheric Glioma, H3 G34-mutant1
Other2 trials
San Francisco, California2 trials
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2
Basking Ridge, New Jersey1 trial
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 1
Brooklyn, New York1 trial
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Brooklyn Methodist Hospital - New York Presbyterian
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.